SIMPARICA CHEWABLES- sarolaner tablet, chewable
Simparica Chewables by
Drug Labeling and Warnings
Simparica Chewables by is a Animal medication manufactured, distributed, or labeled by Zoetis Inc.. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
- SPL UNCLASSIFIED SECTION
- Caution
-
Description
SIMPARICA is a flavored, chewable tablet for administration to dogs over 6 months of age according to their weight. Each tablet is formulated to provide a minimum sarolaner dosage of 0.91 mg/lb (2 mg/kg ) body weight.
Sarolaner is a member of the isoxazoline class of parasiticides and the chemical name is 1-(5'-((5S)-5-(3,5-Dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'-H-spiro(azetidine-3,1'-(2)benzofuran)-1-yl)-2-(methylsulfonyl)ethanone. SIMPARICA contains the S-enantiomer of sarolaner.
The chemical structure of the S-enantiomer of sarolaner is:
Chemical Structure of Simparica
-
INDICATIONS
SIMPARICA kills adult fleas, and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs 6 months of age or older and weighing 2.8 pounds or greater.
-
DOSAGE AND ADMINISTRATION
SIMPARICA is given orally once a month at the recommended minimum dosage of 0.91 mg/lb (2 mg/kg).
Dosage Schedule:
Body Weight
SAROLANER per Tablet (mg)
Number of Tablets Administered
2.8 to 5.5 lbs
5
One
5.6 to 11.0 lbs
10
One
11.1 to 22.0 lbs
20
One
22.1 to 44.0 lbs
40
One
44.1 to 88.0 lbs
80
One
88.1 to 132.0 lbs
120
One
>132.1 lbs
Administer the appropriate combination of tablets
SIMPARICA can be offered by hand, in the food, or administered like other tablet medications.
Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes to ensure that part of the dose is not lost or refused. If a dose is missed, administer SIMPARICA and resume a monthly dosing schedule.
SIMPARICA should be administered at monthly intervals.
Flea Treatment and Prevention:
Treatment with SIMPARICA may begin at any time of the year. In areas where fleas are common year-round, monthly treatment with SIMPARICA can continue the entire year without interruption.
To minimize the likelihood of flea re-infestation, it is important to treat all dogs and cats within a household with an approved flea control product.
Tick Treatment and Control:
Treatment with SIMPARICA can begin at any time of the year (see Effectiveness).
- CONTRAINDICATIONS
- WARNINGS
- PRECAUTIONS
-
ADVERSE REACTIONS
SIMPARICA was administered in a well-controlled US field study, which included a total of 479 dogs (315 dogs treated with SIMPARICA and 164 dogs treated with active control once monthly for three treatments).
Over the 90-day study period, all observations of potential adverse reactions were recorded.Table 1. Dogs with adverse reactions Adverse reaction
sarolaner
sarolaner
active control
active control
N
%
(n = 315)N
#
(n =164)Vomiting
3
0.95%
9
5.50%
Diarrhea
2
0.63%
2
1.20%
Lethargy
1
0.32%
2
1.20%
Inappetence
0
0%
3
1.80%
Additionally, one female dog aged 8.6 years exhibited lethargy, ataxia while posturing to eliminate, elevated third eyelids, and inappetence one day after receiving SIMPARICA concurrently with a heartworm preventative (ivermectin/pyrantel pamoate). The signs resolved one day later. After the day 14 visit, the owner elected to withdraw the dog from the study.
For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Zoetis Inc. at 1-888-963-8471. Additional information can be found at www.SIMPARICA.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/AnimalVeterinary/SafetyHealth.
.
-
CLINICAL PHARMACOLOGY
Sarolaner is rapidly and well absorbed following oral administration of SIMPARICA. In a study of 12 Beagle dogs the mean maximum plasma concentration (Cmax) was 1100 ng/mL and the mean time to maximum concentration (Tmax) occurred at 3 hours following a single oral dose of 2 mg/kg to fasted animals. The mean oral bioavailability was 86% and 107% in fasted and fed dogs, respectively. The mean oral T1/2 values for fasted and fed animals was 10 and 12 days respectively.
Sarolaner is distributed widely; the mean volume of distribution (Vdss) was 2.81 L/kg bodyweight following a 2 mg/kg intravenous dose of sarolaner. Sarolaner is highly bound (≥99.9%) to plasma proteins. The metabolism of sarolaner appears to be minimal in the dog. The primary route of sarolaner elimination from dogs is biliary excretion with elimination via the feces.
Following repeat administration of SIMPARICA once every 28 days for 10 doses to Beagle dogs at 1X, 3X, and 5X the maximum intended clinical dose of 4 mg/kg, steady-state plasma concentrations were reached after the 6th dose. Following treatment at 1X, 3X, and 5X the maximum intended clinical dose of 4 mg/kg, sarolaner systemic exposure was dose proportional over the range 1X to 5X.
-
Mode of Action
The active substance of SIMPARICA, sarolaner, is an acaricide and insecticide belonging to the isoxazoline group. Sarolaner inhibits the function of the neurotransmitter gammaaminobutyric acid (GABA) receptor and glutamate receptor, and works at the neuromuscular junction in insects. This results in uncontrolled neuromuscular activity leading to death in insects or acarines.
.
-
Effectiveness
In a well-controlled laboratory study, SIMPARICA began to kill fleas 3 hours after initial administration and reduced the number of live fleas by ≥96.2% within 8 hours after flea infestation through Day 35.
In a separate well-controlled laboratory study, SIMPARICA demonstrated 100% effectiveness against adult fleas within 24 hours following treatment and maintained 100% effectiveness against weekly re-infestations for 35 days.
In a study to explore flea egg production and viability, SIMPARICA killed fleas before they could lay eggs for 35 days. In a study to simulate a flea-infested home environment, with flea infestations established prior to the start of treatment and re-infestations on Days 7, 37 and 67, SIMPARICA administered monthly for three months demonstrated >95.6% reduction in adult fleas within 14 days after treatment and reached 100% on Day 60.
In well-controlled laboratory studies, SIMPARICA demonstrated ≥99% effectiveness against an initial infestation of Amblyomma americanum, Amblyomma maculatum, Dermacentor variabilis, Ixodes scapularis, and Rhipicephalus sanguineus 48 hours post-administration and maintained >96% effectiveness 48 hours post re-infestation for 30 days.
In a well-controlled 90-day US field study conducted in households with existing flea infestations of varying severity, the effectiveness of SIMPARICA against fleas on Day 30, 60 and 90 visits compared to baseline was 99.4%, 99.8%, and 100%, respectively. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus as a direct result of eliminating fleas.
-
Animal Safety
In a margin of safety study, SIMPARICA was administered orally to 8-week-old Beagle puppies at doses of 0, 1X, 3X, and 5X the maximum recommended dose (4 mg/kg) at 28-day intervals for 10 doses (8 dogs per group). The control group received placebo tablets. No neurologic signs were observed in the 1X group. In the3X group, one male dog exhibited tremors and ataxia post-dose on Day 0; one female dog exhibited tremors on Days 1, 2, 3, and 5; and one female dog exhibited tremors on Day 1. In the 5X group, one female dog had a seizure on Day 61 (5 days after third dose); one female dog had tremors post-dose on Day 0 and abnormal head coordination after dosing on Day 140; and one female dog exhibited seizures associated with the second and fourth doses and tremors associated with the second and third doses. All dogs recovered without treatment. Except for the observation of abnormal head coordination in one dog in the 5X group two hours after dosing on Day 140 (dose 6). There were no treatment-related neurological signs observed once the dogs reached the age of 6 months.
In a separate exploratory pharmacokinetic study, one female dog dosed at 12 mg/kg (3X the maximum recommended dose) exhibited lethargy, anorexia, and multiple neurological signs including ataxia, tremors, disorientation, hypersalivation, diminished proprioception, and absent menace, approximately 2 days after a third monthly dose. The dog was not treated, and was ultimately euthanized. The first two doses resulted in plasma concentrations that were consistent with those of the other dogs in the treatment group. Starting at 7 hours after the third dose, there was a rapid 2.5 fold increase in plasma concentrations within 41 hours, resulting in a Cmax more than 7-fold higher than the mean Cmax at the maximum recommended use dose. No cause for the sudden increase in sarolaner plasma concentrations was identified.
- Storage Information
-
How Supplied
SIMPARICA (sarolaner) Chewables are available in six flavored tablet sizes: 5, 10, 20, 40, 80, and 120 mg. Each tablet size is available in color-coded packages of one, three, or six tablets.
NADA #141-452, Approved by FDA
Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
Made in Switzerland
Revised: June 2017
-
PRINCIPAL DISPLAY PANEL 5 mg Carton
Simparica
(sarolaner) Chewables
Kills fleas before they lay eggs
Kills 5 types of ticks
Protection for a full month
1 liver-flavored tablet controls fleas and ticks for a month
Net Contents: 1 tablet containing 5 mg sarolaner
See back panel for dosing intervals
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA #141-452, Approved by FDA
PRINCIPAL DISPLAY PANEL 5 mg Carton
-
PRINCIPAL DISPLAY PANEL 10 mg Carton
Simparica
(sarolaner) Chewables
Kills fleas before they lay eggs
Kills 5 types of ticks
Protection for a full month
1 liver-flavored tablet controls fleas
and ticks for a month
Net Contents: 1 tablet containing 10 mg sarolaner
See back panel for dosing intervals
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA #141-452, Approved by FDA
PRINCIPAL DISPLAY PANEL 10 mg Carton
-
PRINICIPAL DISPLAY PANEL 20 mg Carton
Simparica
(sarolaner) Chewables
Kills fleas before they lay eggs
Kills 5 types of ticks
Protection for a full month
1 liver-flavored tablet controls fleas
and ticks for a month
Net Contents: 1 tablet containing 20 mg sarolaner
See back panel for dosing intervals
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA #141-452, Approved by FDA
PRINICIPAL DISPLAY PANEL 20 mg Carton
-
PRINCIPAL DISPLAY PANEL 40 mg Carton
Simparica
(sarolaner) Chewables
Kills fleas before they lay eggs
Kills 5 types of ticks
Protection for a full month
1 liver-flavored tablet controls fleas
and ticks for a month
Net Contents: 1 tablet containing 40 mg sarolaner
See back panel for dosing intervals
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA #141-452, Approved by FDA
PRINCIPAL DISPLAY PANEL 40 mg Carton
-
PRINCIPAL DISPLAY PANEL 80 mg Carton
Simparica
(sarolaner) Chewables
Kills fleas before they lay eggs
Kills 5 types of ticks
Protection for a full month
1 liver-flavored tablet controls fleas
and ticks for a month
Net Contents: 1 tablet containing 80 mg sarolaner
See back panel for dosing intervals
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA #141-452, Approved by FDA
PRINCIPAL DISPLAY PANEL 80 mg Carton
-
PRINCIPAL DISPLAY PANEL 120 mg Carton
Simparica
(sarolaner) Chewables
Kills fleas before they lay eggs
Kills 5 types of ticks
Protection for a full month
1 liver-flavored tablet controls fleas
and ticks for a month
Net Contents: 1 tablet containing 120 mg sarolaner
See back panel for dosing intervals
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
NADA #141-452, Approved by FDA
PRINCIPAL DISPLAY PANEL 120 mg Carton
-
INGREDIENTS AND APPEARANCE
SIMPARICA CHEWABLES
sarolaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 54771-2015 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SAROLANER (UNII: DM113FTW7F) (SAROLANER - UNII:DM113FTW7F) SAROLANER 5 mg Inactive Ingredients Ingredient Name Strength HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) (UNII: 1394NXB9L6) STARCH, CORN (UNII: O8232NY3SJ) SUCROSE (UNII: C151H8M554) WHEAT GERM (UNII: YR3G369F5A) ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) CORN SYRUP (UNII: 9G5L16BK6N) GELATIN (UNII: 2G86QN327L) Product Characteristics Color BROWN Score no score Shape SQUARE (Square with rounded edges) Size 6mm Flavor LIVER Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 54771-2015-3 2 in 1 CARTON 1 3 in 1 BLISTER PACK 2 NDC: 54771-2015-1 1 in 1 CARTON 2 1 in 1 BLISTER PACK 3 NDC: 54771-2015-2 1 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141452 02/24/2016 SIMPARICA CHEWABLES
sarolaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 54771-2016 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SAROLANER (UNII: DM113FTW7F) (SAROLANER - UNII:DM113FTW7F) SAROLANER 10 mg Inactive Ingredients Ingredient Name Strength HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) (UNII: 1394NXB9L6) STARCH, CORN (UNII: O8232NY3SJ) SUCROSE (UNII: C151H8M554) WHEAT GERM (UNII: YR3G369F5A) ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) CORN SYRUP (UNII: 9G5L16BK6N) GELATIN (UNII: 2G86QN327L) Product Characteristics Color BROWN Score no score Shape SQUARE (Square with rounded edges) Size 8mm Flavor LIVER Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 54771-2016-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC: 54771-2016-2 1 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC: 54771-2016-3 2 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141452 02/24/2016 SIMPARICA CHEWABLES
sarolaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 54771-2017 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SAROLANER (UNII: DM113FTW7F) (SAROLANER - UNII:DM113FTW7F) SAROLANER 20 mg Inactive Ingredients Ingredient Name Strength HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) (UNII: 1394NXB9L6) STARCH, CORN (UNII: O8232NY3SJ) SUCROSE (UNII: C151H8M554) WHEAT GERM (UNII: YR3G369F5A) ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) CORN SYRUP (UNII: 9G5L16BK6N) GELATIN (UNII: 2G86QN327L) Product Characteristics Color BROWN Score no score Shape SQUARE Size 10mm Flavor LIVER Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 54771-2017-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC: 54771-2017-2 1 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC: 54771-2017-3 2 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141452 02/24/2016 SIMPARICA CHEWABLES
sarolaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 54771-2018 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SAROLANER (UNII: DM113FTW7F) (SAROLANER - UNII:DM113FTW7F) SAROLANER 40 mg Inactive Ingredients Ingredient Name Strength HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) (UNII: 1394NXB9L6) STARCH, CORN (UNII: O8232NY3SJ) SUCROSE (UNII: C151H8M554) WHEAT GERM (UNII: YR3G369F5A) ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) CORN SYRUP (UNII: 9G5L16BK6N) GELATIN (UNII: 2G86QN327L) Product Characteristics Color BROWN Score no score Shape SQUARE Size 14mm Flavor LIVER Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 54771-2018-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC: 54771-2018-2 1 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC: 54771-2018-3 2 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141452 02/24/2016 SIMPARICA CHEWABLES
sarolaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 54771-2019 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SAROLANER (UNII: DM113FTW7F) (SAROLANER - UNII:DM113FTW7F) SAROLANER 80 mg Inactive Ingredients Ingredient Name Strength HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) (UNII: 1394NXB9L6) STARCH, CORN (UNII: O8232NY3SJ) SUCROSE (UNII: C151H8M554) WHEAT GERM (UNII: YR3G369F5A) ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) CORN SYRUP (UNII: 9G5L16BK6N) GELATIN (UNII: 2G86QN327L) Product Characteristics Color BROWN Score no score Shape SQUARE Size 16mm Flavor LIVER Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 54771-2019-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC: 54771-2019-2 1 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC: 54771-2019-3 2 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141452 02/24/2016 SIMPARICA CHEWABLES
sarolaner tablet, chewableProduct Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC: 54771-2020 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength SAROLANER (UNII: DM113FTW7F) (SAROLANER - UNII:DM113FTW7F) SAROLANER 120 mg Inactive Ingredients Ingredient Name Strength HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) (UNII: 1394NXB9L6) STARCH, CORN (UNII: O8232NY3SJ) SUCROSE (UNII: C151H8M554) WHEAT GERM (UNII: YR3G369F5A) ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) CORN SYRUP (UNII: 9G5L16BK6N) GELATIN (UNII: 2G86QN327L) Product Characteristics Color BROWN Score no score Shape SQUARE Size 19mm Flavor LIVER Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 54771-2020-1 1 in 1 CARTON 1 1 in 1 BLISTER PACK 2 NDC: 54771-2020-2 1 in 1 CARTON 2 3 in 1 BLISTER PACK 3 NDC: 54771-2020-3 2 in 1 CARTON 3 3 in 1 BLISTER PACK Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA141452 02/24/2016 Labeler - Zoetis Inc. (828851555) Establishment Name Address ID/FEI Business Operations Siegfried AG 482824026 API MANUFACTURE Establishment Name Address ID/FEI Business Operations Zoetis LLC 039055157 MANUFACTURE
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.